Reported 27 days ago
Eli Lilly is set to advertise its weight-loss drug, Zepbound, for the first time next month, aiming to increase brand awareness amid lower-than-expected sales. Despite generating $1.3 billion in sales this past quarter, below the anticipated $1.7 billion, Lilly is eager to enhance consumer recognition following the FDA's approval in November 2023. The company has identified that only 5% of its market potential has been reached, prompting the need for advertising as it competes against rivals like Novo Nordisk.
Source: YAHOO